GO:0072498Ontology (GO BP)GO biological process · ~15 member genes
Q-omics provides the Embryonic skeletal joint development (GO:0072498) pathway profile, scoring each patient from the combined activity of its roughly 15 member genes. Pathway activity is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, the pathway is differentially active in 13, with the highest sampling consensus in HNSC. Additionally, pathway RNA activity shows 33,709 significant cross-omics associations, again with the highest sampling consensus in HNSC. Together, these results highlight UCS, and HNSC as cancer lineages where the pathway shows reproducible signals across outcome, tissue activity, and molecular association analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns. Pathway-against-pathway and pathway-against-mutation comparisons are not available for ontology entities.
Survival associations
This table summarizes Embryonic skeletal joint development survival associations by molecular data type. RNA-level pathway activity shows survival associations in the most cancer types (28). The rightmost column indicates the cancer type with the highest sampling consensus for each layer.
This table ranks reproducible pathway activity–survival associations across cancer types. High Embryonic skeletal joint development activity shows favorable associations in UCS, UVM, LGG and LUSC, but unfavorable associations in KICH and ESCA. In the UCS Kaplan–Meier curve the low-activity group declines faster, consistent with the favorable association (log-rank p < 0.001). UCS ranks highest by sampling consensus for Embryonic skeletal joint development.
This table summarizes Embryonic skeletal joint development tumor–normal activity differences by data type. RNA-level activity shows significant tumor–normal differences in 13 cancer types, while mass-spec protein activity shows differences in 5. The strongest signals are in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal activity differences for the pathway. A positive fold-change indicates higher activity in tumor tissue. The pathway shows higher tumor activity across COAD and KIRP and lower tumor activity in HNSC, BLCA, LUSC and LUAD. In the HNSC box plot, normal samples show higher pathway activity than tumor samples (log2 FC = −0.041, t-test p < 0.001).
This table shows molecular features associated with Embryonic skeletal joint development pathway activity in patient tissues and cancer cell lines. In patient samples, pathway activity is most strongly linked to RNA and protein features, with the largest associated set in HNSC. In cancer cell lines, RNA-expression features and functional dependencies dominate, with the largest set in BLOOD_Myeloma.
